Reumatologia clinica最新文献

{"title":"The relationship between dietary inflammatory index scores and rheumatoid arthritis disease activity","authors":"Hüseyin Baygin ,&nbsp;Fatih Siriken ,&nbsp;Gökhan Sargın ,&nbsp;Songül Çildag ,&nbsp;Hakan Ozturk ,&nbsp;Taskin Senturk","doi":"10.1016/j.reumae.2024.07.001","DOIUrl":"https://doi.org/10.1016/j.reumae.2024.07.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Many patients diagnosed with rheumatoid arthritis (RA) report relief of symptoms after consuming certain foods. Diet plays a vital role in rheumatoid arthritis-related inflammation regulation. This study investigates the relationship between dietary inflammation index (DII) scores and RA disease activity.</p></div><div><h3>Materials and methods</h3><p>Forty-one RA patients were enrolled in the study. The general inflammatory index of the diet was analyzed by recording the 24-h food consumption of the patients, and the nutrients were analyzed using the Nutrition Information Systems Package Program. Dietary inflammatory indices were calculated for each patient using the patients’ macro and micronutrient intake levels. RA disease activity was assessed using the Disease Activity Score-28 (DAS-28).</p></div><div><h3>Results</h3><p>The DAS-28 score was lower in the anti-inflammatory diet group compared to the pro-inflammatory diet group (<em>p</em> <!-->=<!--> <!-->0.163). A weak but significant relationship was found between diet inflammation index score and DAS-28 (<em>r</em> <!-->=<!--> <!-->0.3468, <em>p</em> <!-->=<!--> <!-->0.0263). The effect of the dietary inflammatory index on the DAS-28 was 12.02%. Dietary iron, vitamin C, niacin, and magnesium intakes were statistically significantly higher in the quartile group that received an anti-inflammatory diet than in the quartile group that received a pro-inflammatory diet. The intake of some micronutrients, such as iron, zinc, magnesium, and folic acid, was significantly lower than the recommended values in all RA quartile groups.</p></div><div><h3>Conclusion</h3><p>Our results suggest that reducing inflammation through the diet may have a weak but significant effect in controlling disease activity in RA patients.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 6","pages":"Pages 305-311"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the COVID-19 pandemic on psychosocial health in rheumatic patients: A longitudinal study","authors":"Laura Cano-García ,&nbsp;Sara Manrique-Arija ,&nbsp;Rocío Redondo-Rodríguez ,&nbsp;Marta Vera-Ruiz ,&nbsp;Jose Manuel Lisbona-Montañez ,&nbsp;Arkaitz Mucientes-Ruiz ,&nbsp;Aimara García-Studer ,&nbsp;Fernando Ortiz-Marquez ,&nbsp;Natalia Mena-Vázquez ,&nbsp;Antonio Fernández-Nebro","doi":"10.1016/j.reumae.2024.03.004","DOIUrl":"https://doi.org/10.1016/j.reumae.2024.03.004","url":null,"abstract":"<div><h3>Aim</h3><p>To describe the impact of the COVID-19 on the psychosocial health of patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), and systemic lupus erythematosus (SLE).</p></div><div><h3>Design</h3><p>Longitudinal observational study of a series of patients with rheumatic disease.</p></div><div><h3>Methods</h3><p>The main outcome measure was impairment of the ability to participate in social activities, as measured using the PROMIS-APS instrument Short Form-8a. We evaluated social activities in various settings and performed a multivariate analysis to study the association between worsening of social participation during the COVID-19 pandemic and implicated factors.</p></div><div><h3>Results</h3><p>One hundred and twenty-five patients had completed the prospective follow-up: 40 with AR (32%), 42 with SpA (33.6%), and 43 with SLE (34.4%). Overall, poorer mean PROMIS scores were recorded after the COVID-19 pandemic for: satisfaction with social roles (<em>p</em> <!-->=<!--> <!-->0.029), depression (<em>p</em> <!-->=<!--> <!-->0.039), and ability to participate in social activities (<em>p</em> <!-->=<!--> <!-->0.024). The factors associated with ability to participate in social activities after the COVID-19 pandemic were older age (<em>β</em> <!-->=<!--> <!-->−0.215; <em>p</em> <!-->=<!--> <!-->0.012), diagnosis of SLE (<em>β</em> <!-->=<!--> <!-->−0.203; <em>p</em> <!-->=<!--> <!-->0.015), depression (<em>β</em> <!-->=<!--> <!-->−0.295; <em>p</em> <!-->=<!--> <!-->0.003) and satisfaction with social roles (<em>β</em> <!-->=<!--> <!-->0.211; <em>p</em> <!-->=<!--> <!-->0.037).</p></div><div><h3>Conclusion</h3><p>The ability to participate in social activities after the COVID-19 pandemic is affected in patients with rheumatic disease, especially in SLE.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 6","pages":"Pages 297-304"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141582075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delphi consensus on the use of telemedicine in rheumatology: RESULTAR study","authors":"Jenaro Graña Gil ,&nbsp;María José Moreno Martínez ,&nbsp;María del Carmen Carrasco Cubero","doi":"10.1016/j.reumae.2024.05.005","DOIUrl":"10.1016/j.reumae.2024.05.005","url":null,"abstract":"<div><h3>Background and objectives</h3><p>There is growing interest in the potential of telemedicine (TM) as an alternative to physical consultation. Although numerous studies prove the benefits of TM in rheumatology, there are no recommendations on its implementation in Spain. The aim of this study was to analyze the application of TM in rheumatology consultations in Spain.</p></div><div><h3>Materials and methods</h3><p>Qualitative, cross-sectional, multicenter study with Delphi methodology in two rounds of queries. A structured ad hoc questionnaire was designed that included statements on teleconsultation, nursing teleconsultation, telecare, telerehabilitation, teleradiology, telehealth tele-education, main barriers, advantages and disadvantages of telehealth tele-education and TM in rheumatoid arthritis. The participants were rheumatology specialists practicing in Spain.</p></div><div><h3>Results</h3><p>The participating rheumatologists (<em>N</em> = 80) had a mean age of 42.4 (±9.0) years, with 12.6 (±8.4) years of experience. Some of the aspects of TM that obtained the greatest consensus were: TM is useful for follow-up of some patients, to help determine if a face-to-face consultation is necessary, or to assist patients with rheumatoid arthritis if they present low activity or in remission; certain patients, such as those in their first consultation or those who present digital barriers or cognitive deterioration, should be seen face-to-face; TM presents some technical and patient access barriers; TM can be useful in nursing and in continued medical education.</p></div><div><h3>Conclusions</h3><p>TM can be beneficial for the treatment and follow-up of patients with rheumatic diseases, as well as for alleviating the face-to-face care burden in rheumatology.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 254-262"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk","authors":"Cristiana Sieiro Santos ,&nbsp;Maria Miguel Oliveira ,&nbsp;Paulo Ney Solari ,&nbsp;Pedro Mateus ,&nbsp;Maria José Santos ,&nbsp;Hector Corominas ,&nbsp;Carolina Álvarez Castro ,&nbsp;Elvira Díez Álvarez","doi":"10.1016/j.reumae.2024.05.002","DOIUrl":"https://doi.org/10.1016/j.reumae.2024.05.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Autoimmune diseases are known to be associated with an elevated risk of cardiovascular diseases; however, there exists a lack of awareness regarding this increased risk among patients.</p></div><div><h3>Objective</h3><p>This study aimed to assess the prevalence of cardiovascular risk factors and events in various systemic autoimmune diseases, including Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's syndrome (SS), matched by age, sex, and disease duration. Additionally, the study aimed to evaluate the perceived and actual risks of cardiovascular disease among patients.</p></div><div><h3>Methods</h3><p>A cross-sectional self-reported survey on the patient's perspective of cardiovascular risk was conducted between January and June 2023. Sociodemographic and clinical data, including disease activity, were collected through medical records and questionnaires. Traditional cardiovascular risk factors and events were assessed, alongside the perceived cardiovascular risk. The SCORE calculation and Charlson Comorbidity Index (CCI) were employed for cardiovascular risk assessment.</p></div><div><h3>Results</h3><p>Survey responses from 180 patients (45 patients each with SSc, SLE, RA, and SS) with systemic autoimmune diseases revealed that 20% perceived a low risk, 23% perceived neither lower nor higher, and 56% perceived a higher risk of developing cardiovascular diseases in the next ten years. Only 45% agreed that their autoimmune disease could increase the risk of a heart attack, even in the absence of other risk factors, and 46.7% were unaware that NSAIDs pose a cardiovascular risk. An association between cardiovascular risk measured by SCORE, comorbidities, and risk perception was observed in RA, SSc, and SS patients, with no association found in SLE patients (<em>p</em> <!-->=<!--> <!-->0.27). Except for SS patients (<em>p</em> <!-->=<!--> <!-->0.02), no association between CCI and disease activity level was found. Regarding the influence of age, working status, and education in CVD risk perception, an association between CVD risk perception and age was observed (<em>p</em> <!-->=<!--> <!-->0.01), with patients over 40 years exhibiting a higher perception of CVD risk. No differences were found regarding working status (<em>p</em> <!-->=<!--> <!-->0.19) nor education level (<em>p</em> <!-->=<!--> <!-->0.06).</p></div><div><h3>Conclusions</h3><p>Patients with SS, RA, and SSc displayed a heightened perception of cardiovascular risk, correlating with their actual risk and preexisting comorbidities. However, patients exhibited unawareness of certain cardiovascular risk behaviors. This underscores the need for tailored education programs on cardiovascular risk for autoimmune disease patients, to be implemented at the time of diagnosis and during follow-up in outpatient clinics.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 229-236"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease","authors":"Rodrigo Lozano-Lozano ,&nbsp;David Vega-Morales ,&nbsp;Macarena del Rosario Sifuentes-Martinez ,&nbsp;Denisse Ornelas-Balcazar","doi":"10.1016/j.reumae.2024.02.010","DOIUrl":"https://doi.org/10.1016/j.reumae.2024.02.010","url":null,"abstract":"<div><h3>Introduction/Aim</h3><p>Older people with rheumatic diseases tend to have a greater number of associated comorbidities, which will require the use of more drugs, increasing the risk of hospitalizations, complications, and drug interactions. In Mexico, there has been an estimated prevalence of polypharmacy of up to 55%, however there are scarce reports on the topic in our elderly population with rheumatic diseases. We aimed to determine the prevalence of polypharmacy and the association of drug interactions in patients treated for rheumatic disease.</p></div><div><h3>Methods</h3><p>A retrospective observational study was conducted on patients undergoing treatment for rheumatic diseases who were treated in geriatrics and rheumatology clinics from January to December 2021. The presence of polypharmacy and drug interactions was evaluated using the BOT Plus Pharmacological Surveillance System. The prevalence of polypharmacy and the association of drug interactions were estimated.</p></div><div><h3>Results</h3><p>We evaluated 320 patients, with a mean age of 67.05<!--> <!-->±<!--> <!-->5.8 years, predominantly female (85%). The prevalence of polypharmacy was 68.1% (<em>n</em> <!-->=<!--> <!-->218), of which 214 (98.1%) patients had related drug interactions; 27.1% were severe and 53.2% as moderate interactions. Factors related with increased risk of drug interactions were being exposed to hypertension increased the risk of drug interactions (POR 1.75, 95% CI 1.44–2.14; <em>P</em> <!-->&lt;<!--> <!-->0.001), having osteoarthritis (POR 1.21, 95% CI 1.04–1.42; <em>P</em> <!-->=<!--> <!-->0.032) and thyroid disease (POR 1.45, 95% CI 1.28–1.65; <em>P</em> <!-->=<!--> <!-->0.001). The most prevalent serious interactions were leflunomide–methotrexate in 27 (46.5%) patients and buprenorphine–tramadol in 8 (13.7%).</p></div><div><h3>Conclusions</h3><p>A high prevalence of polypharmacy and drug interactions was observed in elderly patients with rheumatic diseases. The main associated factors were comorbidities, particularly high blood pressure, osteoarthritis and thyroid diseases.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 249-253"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of the guidelines for the pharmacological treatment of rheumatoid arthritis by the Mexican College of Rheumatology 2023","authors":"Carlos Abud-Mendoza ,&nbsp;Francisco Javier Aceves-Ávila ,&nbsp;César Alejandro Arce-Salinas ,&nbsp;José Álvarez Nemegyei ,&nbsp;Leonor Barile-Fabris ,&nbsp;Sergio Durán-Barragán ,&nbsp;Diana Elsa Flores-Alvarado ,&nbsp;Eufrates Hernández-Núñez ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;José Francisco Moctezuma-Ríos ,&nbsp;Virginia Pascual-Ramos ,&nbsp;Margarita Portela-Hernández ,&nbsp;Luis Humberto Silveira ,&nbsp;Lilia Andrade-Ortega ,&nbsp;Ana Barrera-Vargas ,&nbsp;Sandra Carrillo-Vázquez ,&nbsp;Zully Castro-Colin ,&nbsp;Enrique Cuevas-Orta ,&nbsp;Luis Felipe Flores-Suárez ,&nbsp;Guillermo Arturo Guaracha-Basáñez ,&nbsp;César Pacheco-Tena","doi":"10.1016/j.reumae.2024.02.009","DOIUrl":"10.1016/j.reumae.2024.02.009","url":null,"abstract":"<div><h3>Objective</h3><p>To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA).</p></div><div><h3>Methods</h3><p>A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant. These questions were answered based on the results of a recent systematic literature review (SLR), and the evidence's validity was assessed using the GRADE system, considered a standard for these purposes. Subsequently, the expert group reached consensus on the direction and strength of recommendations through a multi-stage voting process.</p></div><div><h3>Results</h3><p>The updated guidelines for RA treatment stratify various therapeutic options, including different classes of DMARDs (conventional, biologicals, and JAK inhibitors), as well as NSAIDs, glucocorticoids, and analgesics. By consensus, it establishes the use of these in different subpopulations of interest among RA patients and addresses aspects related to vaccination, COVID-19, surgery, pregnancy and lactation, and others.</p></div><div><h3>Conclusions</h3><p>This update of the Mexican guidelines for the pharmacological treatment of RA provides reference points for evidence-based decision-making, recommending patient participation in joint decision-making to achieve the greatest benefit for our patients. It also establishes recommendations for managing a variety of relevant conditions affecting our patients</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 263-280"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141139689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe infections in systemic necrotizing vasculitis","authors":"Claudia Pena,&nbsp;Ana Carolina Costi,&nbsp;Lucila García,&nbsp;Mercedes García","doi":"10.1016/j.reumae.2024.05.004","DOIUrl":"10.1016/j.reumae.2024.05.004","url":null,"abstract":"<div><p>Infections in patients with systemic vasculitis represent one of the main causes of mortality. Corticosteroid use, immunosuppressive therapy, age, associated organic involvement and dialysis dependence are risk factors of infection.</p></div><div><h3>Objectives</h3><p>To determine the prevalence of severe infection and associated factors in patients diagnosed with ANCA-associated vasculitis (AAV) and Polyarteritis Nodosa (PAN).</p></div><div><h3>Methods</h3><p>retrospective study was conduced in a single rheumatology center (2000–2018). We included patients diagnosed with AAV (Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (PAM) and Polyarteritis nodosa (PAN). Serious infectious events requiring hospitalisation or prolonged antibiotic/antiviral treatment, recurrent infection of Herpes Zoster Virus or opportunistic infections were evaluated. Sites of infection, isolated microorganisms and mortality related were analyzed.</p></div><div><h3>Results</h3><p>105 patients were analyzed, follow-up time median 18 m, 58.7% were women and median age was 52 years. Types of vasculitis: 41.9% PAM, 16.2% EPGA, 40% GPA, 1.9% PAN. Constitutional, pulmonary, renal and otorhinolaryngology manifestations were the most frequent.</p></div><div><h3>Prevalence of infection</h3><p>34.2%, with a median of 3 months from diagnosis of vasculitis to the infectious event. Low respiratory tract (42.8%), sepsis (31.4%), and urinary tract (14.3%) were the most common sites of infections. Bacterial aetiology was the most prevalent (67.7%). Mortality at the first event was 14.3% and a 72.2% of patients were in the induction phase of treatment.</p><p>Infectious events were significantly associated with age &gt; 65 years (<em>p</em> = 0.030), presence of lung (<em>p</em> = 0.016) and renal involvement (<em>p</em> = 0.001), BVASv3 &gt; 15, mortality (<em>p</em> = 0.0002).</p></div><div><h3>Conclusions</h3><p>The prevalence of infection was 34.2%. Lower airway infections, septicemia and urinary tract infections were the most prevalent. Infections were associated with renal and pulmonary involvement, age older than 65 years and score BVAS &gt; 15. Severe infections were associated with mortality, especially in elderly patients.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 237-242"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scurvy. A forgotten pseudovasculitis","authors":"Noelia Cabaleiro-Raña ,&nbsp;Diego Santos-Álvarez ,&nbsp;Lucía Romar de las Heras ,&nbsp;Carmen Álvarez-Reguera ,&nbsp;Evelin Cecilia Cervantes Pérez ,&nbsp;Rosa María Hernández Cancela ,&nbsp;Susana Romero-Yuste","doi":"10.1016/j.reumae.2024.05.003","DOIUrl":"10.1016/j.reumae.2024.05.003","url":null,"abstract":"<div><p>Scurvy is a nutritional disease caused by ascorbic acid (vitamin C) deficiency. Althought currently it is a rare disease, we should considerer it in the differential diagnosis of purpura and arthritis in patients with restrictive diets.</p><p>We present the case of a 49-year-old man with a history of a nutritional disorder presented to our hospital with generalized purpura and hemarthros. Following the anamnesis and laboratory findings, rheumatological, infectious and hematological etiologies were excluded. Finally, the diagnosis of scurvy was made upon demostration poor levels of vitamin C and a spectacular response to nutritional supplements. We compare this case with 19 similar cases reported in the medical literature.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 281-285"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141185000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From clots to cuts in antiphospholipid syndrome","authors":"Abihai Lucas Hernández ,&nbsp;Yehuda Shoenfeld","doi":"10.1016/j.reumae.2024.05.001","DOIUrl":"https://doi.org/10.1016/j.reumae.2024.05.001","url":null,"abstract":"","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Page 286"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiopulmonary phenotype in systemic sclerosis associated pulmonary hypertension","authors":"Luis Javier Cajas Santana ,&nbsp;Alejandro Correa Giraldo ,&nbsp;Maria Carolina Torres","doi":"10.1016/j.reumae.2024.01.006","DOIUrl":"https://doi.org/10.1016/j.reumae.2024.01.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Pulmonary hypertension (PH) associated with systemic sclerosis (SSc) increases morbidity and mortality. Cardiopulmonary comorbidities, as per the 2021 PH consensus, play a role in the choice of therapy between monotherapy and combination therapy.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in patients with SSc based on the 2013 ACR/EULAR criteria or very early disease (VEDOSS 2011). PH was considered if they met the following criteria: pulmonary artery systolic pressure (PASP)<!--> <!-->&gt;<!--> <!-->39<!--> <!-->mmHg or peak tricuspid regurgitation velocity (PTRV)<!--> <!-->&gt;<!--> <!-->3.4<!--> <!-->m/s, PASP between 33 and 39<!--> <!-->mmHg or PTRV between 2.9 and 3.4<!--> <!-->m/s plus two additional findings suggestive of PH. PH was classified as type 2 if LVEF<!--> <!-->&lt;<!--> <!-->50% or moderate to severe diastolic dysfunction was present; type 3 if extensive interstitial disease on tomography<!--> <!-->&gt;<!--> <!-->20% or forced vital capacity (FVC)<!--> <!-->&lt;<!--> <!-->75%; type 4 if abnormalities related to embolism were detected on scintigraphy or tomography. If patients did not meet these criteria, they were classified as type 1 PH. Complete data on cardiopulmonary risk factors and other factors were required. The frequency of these factors in the population and differences between groups based on risk factors were estimated.</p></div><div><h3>Results</h3><p>A total of 228 patients were selected. Three had type 2 PH, 24 had type 3, and 40 had type 1 PH, with the majority (75%) having at least one cardiopulmonary risk factor, and 47.5% having more than one. Mild diastolic dysfunction (25%) and hypertension (35%) were the most prevalent. In the type 1 PH group, those with risk factors experienced an increase in the number of years with Raynaud's phenomenon, anticentromere antibodies, and gastrointestinal symptoms (<em>p</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusion</h3><p>In patients with PH, 75% have one, and 45% have two or more risk factors.</p></div>","PeriodicalId":94193,"journal":{"name":"Reumatologia clinica","volume":"20 5","pages":"Pages 243-248"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141325503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}